Dose Finding Consortium (DFC)

At a Glance
  • Status: Completed Consortium
  • Year Launched: 2012
  • Initiating Organization: Cytel
  • Initiator Type: Industry
  • No disease focus
  • Location: North America

Abstract

Mission

The Dose Finding Consortium’s goals are to move the state-of-the-art forward in identifying optimal doses; to encode those practices into commercial validated software; to ease regulatory acceptance with more innovative methods — including adaptive trials — and apply them in practice more quickly.

Consortium History

This cooperative forum, initiated by Cytel in November 2012, addresses the gap left after Pharmaceutical Research and Manufacturers of America (PhRMA) discontinued its Working Group on Adaptive Dose-Ranging Studies in 2011.

Other website

http://www.businesswire.com/news/home/20130413005023/en/Consortium-Addresses-Major-Problem-Biopharmaceutical-Industry-Dose#.VTadQSFVhBc

Sponsors & Partners

Michael Weitz
Director of Marketing
phone: 617-661-2011

Cytel


Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.